Overview
Upper gastrointestinal tract disorders encompass a range of conditions affecting the esophagus, stomach, and duodenum, often requiring endoscopic evaluation and management, frequently necessitating procedural sedation to ensure patient comfort and safety during diagnostic and therapeutic interventions.Diagnosis
Endoscopic visualization to identify lesions, inflammation, or structural abnormalities 123.
Biopsy sampling when necessary to confirm pathological conditions 12.
Assessment of symptoms including dysphagia, abdominal pain, and gastrointestinal bleeding 12.Management
First-line Sedation:
- Remimazolam Tosylate: Effective for sedation with a success rate comparable to propofol, though slower onset but quicker recovery 1.
- Propofol: Commonly used with controlled infusion rates; optimal rate around 500-1000 ml/h to minimize adverse effects like hypoxemia and hypotension 2.
Adjunctive Sedation:
- Intranasal Dexmedetomidine: Used pre-procedurally to reduce overall propofol and alfentanil consumption, enhancing patient satisfaction and reducing sedation depth 3.Special Populations
Elderly: Careful titration of sedatives is crucial due to increased risk of hypotension and respiratory depression; remimazolam may offer quicker recovery benefits 1.
Comorbidities: Patients with cardiovascular conditions should avoid high propofol infusion rates to prevent hypotension 2.Key Recommendations
Use remimazolam tosilate as a non-inferior alternative to propofol for sedation during upper gastrointestinal endoscopy, offering quicker recovery while maintaining efficacy [Evidence: Strong (1)].
Optimize propofol infusion rates between 500-1000 ml/h to balance sedation efficacy with safety, particularly to minimize hypoxemia and hypotension in outpatient settings [Evidence: Moderate (2)].
Consider intranasal dexmedetomidine pre-procedurally to reduce rescue sedation requirements and enhance patient satisfaction in patients undergoing upper gastrointestinal endoscopy [Evidence: Moderate (3)].References
1 Chen SH, Yuan TM, Zhang J, Bai H, Tian M, Pan CX et al.. Remimazolam tosilate in upper gastrointestinal endoscopy: A multicenter, randomized, non-inferiority, phase III trial. Journal of gastroenterology and hepatology 2021. link
2 Li Q, Zhou Q, Xiao W, Zhou H. Determination of the appropriate propofol infusion rate for outpatient upper gastrointestinal endoscopy-a randomized prospective study. BMC gastroenterology 2016. link
3 Cheung CW, Qiu Q, Liu J, Chu KM, Irwin MG. Intranasal dexmedetomidine in combination with patient-controlled sedation during upper gastrointestinal endoscopy: a randomised trial. Acta anaesthesiologica Scandinavica 2015. link